PSA stands for prostate-specific antigen. It is a protein found in prostate cells. It can be detected at a low level in the blood of all adult men.
This article discusses the blood test to measure the amount of PSA in a man's blood.
Prostate-specific antigen; Prostate cancer screening test
How the test is performed:
Blood is typically drawn from a vein, usually from the inside of the elbow or the back of the hand. The site is cleaned with germ-killing medicine (antiseptic). The health care provider wraps an elastic band around the upper arm to apply pressure to the area and make the vein swell with blood.
Next, the health care provider gently inserts a needle into the vein. The blood collects into an airtight vial or tube attached to the needle. The elastic band is removed from your arm. Once the blood has been collected, the needle is removed, and the puncture site is covered to stop any bleeding.
How to prepare for the test:
No special preparation is usually needed.
How the test will feel:
When the needle is inserted to draw blood, some people feel moderate pain while others feel only a prick or stinging sensation. Afterward, there may be some throbbing or a bruise.
Why the test is performed:
This test is done to screen for prostate cancer. It is also used to monitor patients after prostate cancer treatment.
Several conditions besides cancer can cause the PSA level to rise, including:
Discuss with your doctor or health care provider whether a PSA test is appropriate for you.
Normal values vary with age. Older men typically have slightly higher PSA measurements than younger men. Men with a larger prostate will also have higher PSA values.
Normal value ranges may vary slightly among different laboratories. Talk to your doctor about the meaning of your specific test results.
What abnormal results mean:
A high PSA level has been linked to an increased chance of having prostate cancer. However, a high PSA level does not mean that you definitely have prostate cancer. A high PSA level only identifies patients at higher risk of having prostate cancer. People at higher risk may need to have more tests.
A PSA of 4 nanograms per milliliter (ng/mL) is abnormally high for most men and may indicate the need for a prostate biopsy. For men under age 50, levels above 2 ng/mL may be too high. A significant rise from one year to the next may also indicate a higher risk of having prostate cancer.
Keep in mind that although PSA testing is an important tool for detecting prostate cancer, it is not foolproof.
Greater-than-normal PSA levels may indicate:
What the risks are:
Veins and arteries vary in size from one patient to another and from one side of the body to the other. Obtaining a blood sample from some people may be more difficult than from others.
Other risks associated with having blood drawn are slight but may include:
- Excessive bleeding
- Fainting or feeling light-headed
- Hematoma (blood accumulating under the skin)
- Infection (a slight risk any time the skin is broken)
Discuss the benefits and risks of testing with your doctor to determine whether screening is right for you.
- Potential benefits include early diagnosis of cancer
- Potential risks include increased health care costs, unnecessary invasive testing (biopsy) and treatment
The American Urologic Association, American Cancer Society, and National Comprehensive Cancer Network recommend that:
- All men ages 40 - 75 have annual PSA tests
- Screening should also include a prostate examination by your doctor
However, these guidelines are not recommended for everyone. Many health organizations, including the US Preventive Services Task Force, do not recommend routine PSA testing.
American Urological Association. Prostate-specific antigen best practice statement: 2009 update . April 2009. Accessed July 10, 2009.
Lin K, Lipsitz R, Miller T, Janakiraman S. U.S. Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:192-199.
Lim LS, Sherin K; ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med. 2008;34:164-170.
Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med. 2007;357:2696-2705.
Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336-2342.